Humana (NYSE:HUM – Get Free Report) issued its quarterly earnings data on Wednesday. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11, RTT News reports. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the business posted $9.38 earnings per share. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. Humana updated its FY24 guidance to approx. $16.00 EPS.
Humana Price Performance
Humana stock opened at $305.91 on Friday. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The company has a fifty day simple moving average of $327.77 and a 200-day simple moving average of $394.49. The stock has a market cap of $36.86 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45. Humana has a 12-month low of $299.23 and a 12-month high of $541.21.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. Humana’s payout ratio is 22.04%.
Insider Activity at Humana
Wall Street Analyst Weigh In
HUM has been the topic of several research analyst reports. Stephens reduced their price objective on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Oppenheimer reduced their price target on shares of Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research note on Thursday. Truist Financial reaffirmed a “hold” rating and set a $550.00 price objective on shares of Humana in a research report on Friday, January 19th. The Goldman Sachs Group cut their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Finally, Cantor Fitzgerald lowered their price target on Humana from $391.00 to $360.00 and set a “neutral” rating for the company in a research report on Thursday. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $433.74.
Get Our Latest Report on Humana
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- Investing In Automotive Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- How to Calculate Inflation Rate
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to invest in blue chip stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.